Track market-moving stories before they get noisy

You are now leaving Barron's websiteBy clicking on the “Proceed” button below, you will be redirected to a third-party website owned and operated by Hong Kong Tiimoot Information Technology Co., Limited. (“HKT”), which is located in Hong Kong. That website operates independently from Barron's and Barron's does not control the website. The privacy practices of HKT are subject to its Privacy Statement, so please read it closely. We are not responsible for HKT's privacy or other data-related practices.

Micron stock has staged a strong recovery this week, reaching near its highest level since July 2nd this year.

MU jumped to $1,016, up by nearly 40% from its lowest level in July, and technical and fundamental factors suggest further upside.

The daily chart shows that the MU stock has been in a strong rebound in the past few days, rising from a low of $736 in July to the current $1,016.

This rebound has coincided with that of other memory companies like SanDisk, Samsung Electronics, and SK Hynix.

The stock remains above the ascending trendline that links the lowest levels since August 6 of this year.

It has remained above the 50-day Exponential Moving Average (EMA), which has provided it with substantial support.

The Relative Strength Index (RSI) has jumped to 60, its highest level since June 29 this year.

This is a sign that the stock is gaining momentum as investors buy the recent dip. 

It has remained above the Ichimoku cloud and the Supertrend indicator.

Therefore, there is a likelihood that the stock will continue rising as bulls target the next key resistance level of $1,253, its highest level this year.

This target is about 22% above the current level. A move above that level will point to more gains.

MU stock chart | Source: TradingView

Micron is a top company in the high-bandwidth memory (HBM) industry, where it competes with top firms like SK Hynix and Samsung Electronics. 

The company’s business is firing on all cylinders as the artificial intelligence boom continues.

Just recently, its top clients like Nvidia, AMD, Google, and Amazon published strong financial results and boosted their forward guidance.

These numbers suggested that the companies will continue buying from Micron in the near term.

Micron’s last financial results showed that its growth accelerated in the third quarter, reaching $41.5 billion.

Revenue increased 74% from the second quarter and 346% from the same period a year earlier.

The company’s management believes that this growth will continue in the foreseeable future, with the fourth quarter rising to over $50 billion.

And this growth is expected in the coming years, with its revenue expected to hit $242 billion next year.

The company is benefiting from the rising demand for memory chips and the fact that the supply remains tight.

While Micron, Samsung, and SK Hynix are expanding their capacity, this supply will come online in the next few years.

Most importantly, there are signs that Micron is highly undervalued, with its forward price-to-earnings ratio being 13.85. In contrast, the S&P 500 Index has a multiple of 19.9, while the technology sector has a multiple of 22. Its Rule-of-40 multiple is even better.

The revenue and profitability growth, coupled with its valuation, explains why analysts are highly bullish on the company.

Data shows that the average target among analysts is $1,295, up by 27% from the current level. 

The next important catalyst for Micron shares will be the upcoming earnings later this month. Analysts expect these numbers to show that its revenue jumped to over $50 billion during the quarter.

READ MORE: Micron stock analysis as the AI Bubble Index sinks to a four-month low 

SK hynix Inc. is rated Strong Buy over Micron Technology, Inc., rated Buy, on superior HBM leadership and its position in the emerging HBF standard. SKHY holds 50% of the HBM market, double its DRAM share, and began mass-production shipments of HBM4 in the second quarter. Every memory supplier says the supply cannot respond before 2028, with SK hynix's CEO seeing a shortage through 2030, underpinning pricing and earnings.

Micron Technology, Inc. expects 2027 supply conditions to tighten further as AI demand accelerates and DRAM remains a critical infrastructure constraint. HBM3E consumes roughly three times DDR wafer capacity, while HBM4E pushes that trade ratio toward four times. Sixteen strategic customer agreements carried $22 billion in commitments, potentially creating substantially greater earnings visibility through 2030.

Micron (MU - Free Report) closed the most recent trading day at $1,000.26, moving -1.61% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.58%. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%.

The chipmaker's shares have seen an increase of 18.07% over the last month, surpassing the Computer and Technology sector's gain of 0.12% and the S&P 500's loss of 0.36%.

Market participants will be closely following the financial results of Micron in its upcoming release. The company plans to announce its earnings on September 30, 2026. The company is forecasted to report an EPS of $31.39, showcasing a 935.97% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $50.76 billion, up 348.58% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $73.86 per share and a revenue of $129.61 billion, demonstrating changes of +790.95% and +246.76%, respectively, from the preceding year.

Investors should also pay attention to any latest changes in analyst estimates for Micron. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.01% higher within the past month. Micron presently features a Zacks Rank of #2 (Buy).

Digging into valuation, Micron currently has a Forward P/E ratio of 6.44. This valuation marks a discount compared to its industry average Forward P/E of 21.01.

It's also important to note that MU currently trades at a PEG ratio of 0.64. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. MU's industry had an average PEG ratio of 0.64 as of yesterday's close.

The Computer - Integrated Systems industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 29, putting it in the top 12% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

In the latest trading session, Intuitive Surgical, Inc. (ISRG - Free Report) closed at $350.16, marking a -4.51% move from the previous day. This change lagged the S&P 500's 0.58% loss on the day. At the same time, the Dow lost 1.18%, and the tech-heavy Nasdaq lost 0.32%.

The stock of company has fallen by 6.78% in the past month, lagging the Medical sector's gain of 2.73% and the S&P 500's loss of 0.36%.

The investment community will be closely monitoring the performance of Intuitive Surgical, Inc. in its forthcoming earnings report. It is anticipated that the company will report an EPS of $2.61, marking a 8.75% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $2.88 billion, up 14.98% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of $10.74 per share and revenue of $11.81 billion, which would represent changes of +20.27% and +17.38%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for Intuitive Surgical, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Intuitive Surgical, Inc. holds a Zacks Rank of #3 (Hold).

In the context of valuation, Intuitive Surgical, Inc. is at present trading with a Forward P/E ratio of 34.16. This expresses a premium compared to the average Forward P/E of 22.07 of its industry.

Also, we should mention that ISRG has a PEG ratio of 2.29. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical - Instruments industry stood at 2.33 at the close of the market yesterday.

The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 99, putting it in the top 41% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

GRAPEVINE, Texas--(BUSINESS WIRE)--GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today released financial results for the second quarter ended August 1, 2026. The Company's condensed and consolidated financial statements, including GAAP and non-GAAP results, are below. SECOND QUARTER HIGHLIGHTS Operating income of $160.2 million was the highest second quarter operating income in GameStop's history. Collectibles net sales grew 57% year over year to $356.3 million and now represent 45.

GameStop Corp. (NYSE:GME) reported financial results for the second quarter before the market open on Tuesday. Here’s a rundown of the report.

GameStop stock is trending. What’s the outlook for GME shares? GameStop Q2 HighlightsGameStop reported second-quarter revenue of $790.20 million, beating analyst estimates of $756.85 million, according to Benzinga Pro. The company reported adjusted earnings of 27 cents per share for the quarter, in line with analyst estimates.

Total revenue was down approximately 18.72% on a year-over-year basis, driven by the prior-year launch of Nintendo Switch 2, planned store closures and the divestiture of the company’s France operations.

Beginning this quarter, GameStop started reporting net sales in three categories (Collectibles, Video Games, and Pre-Owned and Refurbished). Here’s a breakdown of revenue by category:

Collectibles: $356.3 million, up from $227.6 million year-over-year Video Games: $263.2 million, down from $494.6 million year-over-year Pre-Owned and Refurbished: $170.7 million, down from $250 million year-over-year The Collectibles category stood out with 57% year-over-year growth, representing 45.1% of total net sales in the period.

Operating income totaled $160.2 million in the quarter, representing the highest second quarter operating income in company history. The strong operating performance prompted GameStop to raise its fiscal 2026 adjusted EBITDA outlook to “in excess” of $650 million, up from a prior outlook of more than $600 million.

GameStop said it ended the quarter with $5.4 billion in total cash, cash equivalents, marketable securities, digital assets and related receivables. The company noted that it held approximately 43.4 million shares of eBay common stock at quarter’s end.

GME Shares Move Higher TuesdayGME Price Action: GameStop shares were up 1.10% on Tuesday, trading at $19.37 at the time of publication, according to Benzinga Pro.

Read Next

Image: Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Lisa Martin helps investors explain why GameStop (GME) had its best second quarter, per its preliminary earnings, on record despite concerns of slowing growth. Her big question for GameStop: what is the company becoming?

-

For the first time ever, fans can watch the world’s best Rocket League teams compete for a $1.2 million prize pool on the big screen at select AMC locations on September 20

Attendees will receive a commemorative Rocket League ticket with a code to redeem in-game cosmetics

Tickets are on sale now for the approximately eight-hour live event

LEAWOOD, Kan.--(BUSINESS WIRE)--AMC Theatres® (NYSE: AMC), the largest theatrical exhibitor in the United States and the world, today announced an AMC-exclusive live broadcast of the 2026 Rocket League World Championship Finals at 50 AMC theatres nationwide.

On Sunday, September 20, fans at 50 select AMC locations across the United States will be able to watch the championship Finals streamed live from Dickies Arena in Fort Worth, Texas, where the world's top Rocket League teams compete for a share of the tournament's $1.2 million prize pool and the opportunity to be crowned Rocket League World Champions. This final day of competition will determine the 2026 World Champions in one of esports’ most popular and fast-paced games.

Tickets are on sale now at participating AMC locations – 2026 Rocket League World Championship at AMC Theatres. The event is expected to screen for approximately eight hours and will conclude with the crowning of the 2026 Rocket League World Champions. In addition to experiencing the event on the big screen, all attendees will receive a commemorative Rocket League ticket that has codes to redeem drops you would earn by watching on Twitch.

“Such a big part of the magic of movie theatres is their ability to bring people together for unforgettable shared experiences, and a live event like the Rocket League World Championship is a great example of that," said Ellen Copaken, SVP, Business Development, AMC Theatres. "We're excited to give fans the opportunity to watch esports' biggest stage unfold live on massive screens, surrounded by fellow Rocket League fans.”

A list of participating AMC locations is below. For tickets, visit AMCTheatres.com or the AMC mobile app.

Atlanta
AMC Southlake 24
AMC Sugarloaf Mills 18
Baltimore
AMC Owings Mills 17
Boston
AMC Methuen 20
Charlotte
AMC Carolina Pavilion 22
AMC Concord Mills 24
Chicago
AMC Crestwood 18
AMC South Barrington 24
AMC Village Crossing 18
Columbus
AMC Dublin Village 18
Dallas
AMC Mesquite 30
AMC Stonebriar Mall 24
Denver
AMC Highlands Ranch 24
AMC Westminster Promenade 24
Houston
AMC Fountains 18
AMC Gulf Pointe 30
AMC Willowbrook 24
Indianapolis
AMC Castleton Square 14
AMC Indianapolis 17
Jacksonville
AMC Orange Park 24
AMC Regency 24
Kansas City
AMC Barrywoods 24
Las Vegas
AMC Rainbow Promenade 10
AMC Town Square 18
Los Angeles
AMC Burbank 16
AMC DINE-IN Ontario Mills 30
AMC Orange 30
AMC Rolling Hills 20
Miami
AMC Aventura Mall 24
Minneapolis
AMC Eden Prairie Mall 18
Nashville
AMC Thoroughbred 20
New York
AMC Garden State Plaza 16
AMC Jersey Gardens 20
AMC Kips Bay 15
Oklahoma City
AMC Quail Springs Mall 24
Orlando
AMC DINE-IN Disney Springs 24
Philadelphia
AMC Cherry Hill 24
AMC Neshaminy 24
Phoenix
AMC Ahwatukee 24
AMC Deer Valley 17
Pittsburgh
AMC Waterfront 22
Sacramento
AMC Manteca 16
San Diego
AMC Fashion Valley 18
San Francisco
AMC Bay Street 16
AMC Mercado 20
Seattle
AMC Southcenter 16
Tampa
AMC Highwoods 20
AMC Woodlands Square 20
Washington, DC
AMC DINE-IN Rio Cinemas 18
AMC Hoffman Center 22

ABOUT AMC ENTERTAINMENT HOLDINGS, INC.

AMC is the largest movie exhibition company in the United States, the largest in Europe and the largest throughout the world with approximately 850 theatres and 9,600 screens across the globe. AMC has propelled innovation in the exhibition industry by: deploying its signature power-recliner seats; delivering enhanced food and beverage choices; generating greater guest engagement through its loyalty and subscription programs, website, and mobile apps; offering premium large format experiences and playing a wide variety of content including the latest Hollywood releases and independent programming. For more information, visit amctheatres.com.

More News From AMC Entertainment Holdings, Inc.

Back to Newsroom

Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone

Study Also Met Secondary Progression-Free Survival and Objective Response Rate Endpoints 

, /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone. This study tested IMDELLTRA as a first-line maintenance treatment for people with extensive stage small cell lung cancer (ES-SCLC) whose disease had not progressed following initial treatment with durvalumab, platinum-based chemotherapy and etoposide. The study also demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and objective response rate (ORR) among patients treated with IMDELLTRA in combination with durvalumab.

Overall, the safety profile of IMDELLTRA in combination with durvalumab was consistent with the known safety profiles of the individual medicines. No new or unexpected safety signals were identified in DeLLphi-305. The study design included monitoring in a healthcare setting for 1 to 2 hours (6 to 8 hours in certain regions including Europe) following IMDELLTRA infusion on Cycle 1 Day 1 and Cycle 1 Day 8.

"IMDELLTRA has already revolutionized the standard of survival for patients with extensive stage small cell lung cancer whose disease progressed on or after prior treatment. These landmark results from DeLLphi-305 suggest IMDELLTRA will further revolutionize the standard for survival earlier in the treatment journey and meaningfully shift the treatment paradigm for people facing this devastating disease," said Jay Bradner, M.D., executive vice president, Research and Development, Artificial Intelligence and Data at Amgen. "Despite clinical advances, extensive stage small cell lung cancer remains one of the most aggressive and difficult-to-treat cancers, and substantial improvements in survival are rare, underscoring the importance of these findings."

This marks the first Phase 3 study including a Bispecific T-cell Engager (BiTE®) therapy to demonstrate an overall survival benefit in the first-line maintenance setting for ES-SCLC.

"Given the aggressive nature of small cell lung cancer, many patients quickly relapse on current therapy and never reach second-line treatment. These patients do not have time to wait, making substantial progress in the first-line setting critically important," said Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute. "In my career treating people with extensive stage small cell lung cancer, these are among the most compelling survival results I have seen, indicating the potential to reshape the natural history of small cell lung cancer. DeLLphi-305 represents an unprecedented milestone and suggests we may be entering a new era where meaningfully longer survival is possible for more patients."

Following the U.S. Food and Drug Administration (FDA) approval of IMDELLTRA for adults with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy, the robust global DeLLphi clinical trial program has continued to evaluate its potential across earlier stages of disease and lines of treatment, both as a monotherapy and in combination regimens. Building on the DeLLphi-303 trial, which showed very encouraging efficacy and tolerability results for IMDELLTRA in combination with anti-PD-L1 checkpoint inhibitors in the treatment of first-line ES-SCLC, DeLLphi-305 was designed to evaluate IMDELLTRA earlier in the course of disease, where more patients with SCLC may have the opportunity to benefit.

SCLC is one of the most aggressive forms of lung cancer, accounting for approximately 13-15% of the more than 2.6 million lung cancer cases diagnosed worldwide each year.1-3 Despite advances in the treatment of ES-SCLC, outcomes remain poor, with a median survival of approximately one year from the start of first-line maintenance treatment and only about 40% of patients receiving second-line therapy.4-7

Amgen plans to present detailed data from DeLLphi-305 at an upcoming international medical congress and share it with regulatory authorities.

About the Phase 3 DeLLphi-305 Study
The DeLLphi-305 trial is sponsored by Amgen, with partial funding and durvalumab provided by AstraZeneca. It is a global Phase 3, randomized, open-label clinical trial evaluating the efficacy and safety of IMDELLTRA in combination with durvalumab compared to durvalumab alone as first-line maintenance treatment for patients with ES-SCLC who had not progressed following treatment with durvalumab, platinum-based chemotherapy and etoposide. Five hundred and sixty-three patients who completed initial treatment with durvalumab, platinum-based chemotherapy and etoposide were randomized 1:1 to receive either IMDELLTRA in combination with durvalumab or durvalumab alone until progression or unacceptable toxicity. Following IMDELLTRA infusion on Cycle 1 Day 1 and Cycle 1 Day 8, patients were monitored in a healthcare setting for 1 to 2 hours (6 to 8 hours in certain regions including Europe). The trial included patients with both treated and untreated asymptomatic brain metastases at baseline. The primary outcome measure of the trial is OS. Secondary endpoints include progression-free survival (PFS) and objective response rate (ORR).8

About Tarlatamab Clinical Trials 
Tarlatamab is being investigated in multiple studies including DeLLphi-303, a Phase 1b study investigating tarlatamab in combination with standard-of-care (SOC) therapies in first-line ES-SCLC; DeLLphi-304, a randomized Phase 3 study comparing tarlatamab monotherapy with SOC chemotherapy in second-line treatment of SCLC; DeLLphi-305, a randomized Phase 3 study comparing tarlatamab in combination with durvalumab vs. durvalumab alone as first-line maintenance treatment in ES-SCLC; DeLLphi-306, a randomized placebo-controlled Phase 3 study of tarlatamab following concurrent chemoradiotherapy in limited-stage SCLC; DeLLphi-308, a Phase 1b study evaluating subcutaneous tarlatamab in second-line or later ES-SCLC; DeLLphi-309, a Phase 2 study evaluating alternative intravenous dosing regimens with tarlatamab in second-line ES-SCLC; DeLLphi-310, a Phase 1b study of tarlatamab in combination with YL201 with or without durvalumab in patients with ES-SCLC; DeLLphi-311, a Phase 1b study of tarlatamab in combination with etakafusp alfa (AB248), a novel CD8+ T-cell selective interleukin-2 (IL-2), in patients with ES-SCLC; DeLLphi-312, a randomized Phase 3 study evaluating tarlatamab in combination with durvalumab, carboplatin and etoposide as an induction and maintenance therapy in first-line treatment of ES-SCLC; DeLLphi-313, a Phase 1b study of tarlatamab in combination with zocilurtatug pelitecan, a DLL3 targeting antibody drug conjugate, with and without durvalumab in patients with ES-SCLC, and DeLLphi-315, a Phase 3 study of subcutaneous tarlatamab in patients with second-line ES-SCLC.9

For more information, please visit www.tarlatamabclinicaltrials.com. 

About IMDELLTRA® (tarlatamab-dlle) 
IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen researchers to bind to both DLL3 on tumor cells and CD3 on T cells, thereby activating T cells to kill DLL3-expressing SCLC cells. This results in the formation of a cytolytic synapse with lysis of the cancer cell.10,11 DLL3 is a protein that is expressed on the surface of SCLC cells in ~85-96% of patients with SCLC, but is minimally expressed on healthy cells, making it an exciting target.12,13

U.S. INDICATION
IMDELLTRA® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. 

IMDELLTRA IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 

Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving IMDELLTRA®. Initiate treatment with IMDELLTRA® using the step-up dosing schedule to reduce the incidence and severity of CRS. Withhold IMDELLTRA® until CRS resolves or permanently discontinue based on severity.  Neurologic toxicity and immune effector cell-associated neurotoxicity syndrome (ICANS), including life-threatening or fatal reactions, can occur in patients receiving IMDELLTRA®. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment and treat promptly. Withhold IMDELLTRA® until ICANS resolves or permanently discontinue based on severity.  WARNINGS AND PRECAUTIONS 

Cytokine Release Syndrome (CRS): IMDELLTRA® can cause CRS including life-threatening or fatal reactions. In the pooled safety population, CRS occurred in 57% (268/473) of patients who received IMDELLTRA®, including 39% Grade 1, 15% Grade 2, 1.7% Grade 3 and 0.2% Grade 4. Recurrent CRS occurred in 24% of IMDELLTRA®-treated patients including 20% Grade 1 and 3.4% Grade 2; one patient experienced recurrent Grade 3. Among the 268 patients who experienced CRS, 73% had CRS after the first dose, 60% had CRS after the second dose, and 15% had CRS following the third or later dose. Following the Cycle 1 Day 1, Day 8, Day 15 infusions, 24%, 8%, and 1% of patients experienced Grade ≥ 2 CRS, respectively. From Cycle 2 onwards, 1.5% of patients experienced Grade ≥ 2 CRS. Of the patients who experienced CRS, 31% received steroids and 10% required tocilizumab. The median time to onset of all grade CRS from most recent dose of IMDELLTRA® was 16 hours (range: start of infusion to 15 days). The median time to onset of Grade ≥ 2 CRS from most recent dose of IMDELLTRA® was 15 hours (range: start of infusion to 15 days).

Clinical signs and symptoms of CRS included pyrexia, hypotension, fatigue, tachycardia, headache, hypoxia, nausea, and vomiting. Potentially life-threatening complications of CRS may include cardiac dysfunction, acute respiratory distress syndrome, neurologic toxicity, renal and/or hepatic failure, and disseminated intravascular coagulation (DIC).

Administer IMDELLTRA® following the recommended step-up dosing and administer concomitant medications before and after Cycle 1 Day 1 and Cycle 1 Day 8 IMDELLTRA® infusions as described in Table 3 of the Prescribing Information (PI) to reduce the risk of CRS. Administer IMDELLTRA® in an appropriate healthcare facility equipped to monitor and manage CRS. Ensure patients are well hydrated prior to administration of IMDELLTRA®.

Closely monitor patients for signs and symptoms of CRS during treatment with IMDELLTRA®. At the first sign of CRS, immediately discontinue IMDELLTRA® infusion, evaluate the patient for hospitalization and institute supportive care based on severity. Withhold or permanently discontinue IMDELLTRA® based on severity. Counsel patients and caregivers to seek medical attention should signs or symptoms of CRS occur.

Neurologic Toxicity, Including ICANS: IMDELLTRA® can cause life-threatening or fatal neurologic toxicity, including ICANS. In the pooled safety population, neurologic toxicity occurred in 65% of patients who received IMDELLTRA®, with Grade 3 or higher events in 7% of patients including fatal events in 0.2%. The most frequent neurologic toxicities were dysgeusia (34%), headache (17%), peripheral neuropathy (9%), dizziness (9%), and insomnia (8%). The incidence of signs and symptoms consistent with ICANS was 10% in IMDELLTRA®-treated patients including events with the preferred terms: ICANS (4.7%), muscular weakness (3.2%), cognitive disorder (0.6%), aphasia (0.6%), depressed level of consciousness (0.4%), seizures (0.4%), encephalopathy (0.4%), and leukoencephalopathy (0.2%). There was one fatal reaction of ICANS. Recurrent ICANS occurred in 1.5% of patients. Of the patients who experienced ICANS, most experienced the event following Cycle 1 Day 1 (2.5%) and Cycle 1 Day 8 (3.6%). Following Day 1, Day 8, and Day 15 infusions, 1.3%, 1.3% and 0.4% of patients experienced Grade ≥ 2 ICANS, respectively. ICANS can occur several weeks following administration of IMDELLTRA®. The median time to onset of ICANS from the first dose of IMDELLTRA® was 16 days (range: 1 to 862 days). The median time to resolution of ICANS was 4 days (range: 1 to 40 days). The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Clinical signs and symptoms of ICANS may include but are not limited to confusional state, depressed level of consciousness, disorientation, somnolence, lethargy, and bradyphrenia.

Patients receiving IMDELLTRA® are at risk of neurologic adverse reactions and ICANS resulting in depressed level of consciousness. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, until neurologic symptoms resolve.

Closely monitor patients for signs and symptoms of neurologic toxicity and ICANS during treatment with IMDELLTRA®. At the first sign of ICANS, immediately discontinue the infusion, evaluate the patient and provide supportive therapy based on severity. Withhold IMDELLTRA® or permanently discontinue based on severity.

Cytopenias: IMDELLTRA® can cause cytopenias including neutropenia, thrombocytopenia, and anemia. In the pooled safety population, based on laboratory data, decreased neutrophils occurred in 16% of patients, including 9% Grade 3 or 4. The median time to onset for Grade 3 or 4 decreased neutrophil count was 41 days (range: 2 to 306 days). Decreased platelets occurred in 30% including 2.2% Grade 3 or 4. The median time to onset for Grade 3 or 4 decreased platelets was 67 days (range: 3 to 420 days). Decreased hemoglobin occurred in 56% of patients, including 4.7% Grade 3 or 4. Febrile neutropenia was reported as an adverse event in 1.5% of patients treated with IMDELLTRA®.

Monitor patients for signs and symptoms of cytopenias. Perform complete blood counts prior to treatment with all doses of IMDELLTRA®, up through Cycle 5 Day 15 and then prior to administration on Day 1 of each cycle starting with Cycle 6. Based on the severity of cytopenias, temporarily withhold, or permanently discontinue IMDELLTRA®.

Infections: IMDELLTRA® can cause serious infections, including life-threatening and fatal infections. In the pooled safety population, infections, including opportunistic infections, occurred in 43% of patients who received IMDELLTRA®, including 14% Grade 3 or 4. The most frequent infections were pneumonia (11%), urinary tract infection (9%), COVID-19 (6%), upper respiratory tract infection (4.7%), respiratory tract infection (4%), candida infection (2.1%), oral candidiasis (2.1%), and nasopharyngitis (2.1%).

Monitor patients for signs and symptoms of infection prior to and during treatment with IMDELLTRA® and treat as clinically indicated. Withhold or permanently discontinue IMDELLTRA® based on severity.

Hepatotoxicity: IMDELLTRA® can cause hepatotoxicity. In the pooled safety population, based on laboratory data, elevated ALT occurred in 39% of patients who received IMDELLTRA®, including 2.5% with Grade 3 or 4 ALT. Elevated AST occurred in 43% of patients, including 3.2% Grade 3 or 4. Elevated bilirubin also occurred in 16% of patients, including 1.3% Grade 3 or 4. Liver enzyme elevation can occur with or without concurrent CRS. Monitor liver enzymes and bilirubin prior to treatment with IMDELLTRA®, and as clinically indicated. Withhold IMDELLTRA® or permanently discontinue based on severity.

Hypersensitivity: IMDELLTRA® can cause severe hypersensitivity reactions. Clinical signs and symptoms of hypersensitivity may include, but are not limited to, rash and bronchospasm. Monitor patients for signs and symptoms of hypersensitivity during treatment with IMDELLTRA® and manage as clinically indicated. Withhold or consider permanent discontinuation of IMDELLTRA® based on severity.  Embryo-Fetal Toxicity: Based on its mechanism of action, IMDELLTRA® may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with IMDELLTRA® and for 2 months after the last dose.  ADVERSE REACTIONS  

The pooled safety population reflects exposure to intravenous IMDELLTRA®, as a single agent, at the recommended dosage of IMDELLTRA® 1 mg on Cycle 1 Day 1 followed by 10 mg on Days 8 and 15, and then every 2 weeks until disease progression or intolerable toxicity in 473 patients with small cell lung cancer enrolled in three clinical trials: DeLLphi-300, DeLLphi-301 and DeLLphi-304. Among 473 patients who received IMDELLTRA®, 40% were exposed for 6 months or longer and 19% were exposed for greater than one year.  The most common (≥ 20%) adverse reactions were CRS (57%), fatigue (48%), decreased appetite (38%), dysgeusia (34%), pyrexia (33%), constipation (31%), musculoskeletal pain (31%) and nausea (25%).  The most common (≥ 5%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes (43%), decreased sodium (12%), decreased total neutrophils (9%) and increased uric acid (6%).  DOSAGE AND ADMINISTRATION: Important Dosing Information  

Administer IMDELLTRA® as an intravenous infusion over 1 hour. Administer IMDELLTRA® according to the step-up dose and schedule in the IMDELLTRA® PI (Table 1) to reduce the incidence and severity of CRS. Evaluate complete blood count, liver enzymes and bilirubin prior to administration of all doses of IMDELLTRA® up through Cycle 5 Day 15 and then prior to administration of IMDELLTRA® on Day 1 of each cycle starting with Cycle 6. More frequent evaluation may be necessary if clinically indicated. For Cycle 1, administer recommended concomitant medications before and after Cycle 1 Day 1 and Cycle 1 Day 8 IMDELLTRA® infusions to reduce the risk of CRS reactions as described in the PI (Table 3). IMDELLTRA® should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions such as CRS and neurologic toxicity including ICANS. Due to the risk of CRS and neurologic toxicity, including ICANS, monitor patients from the start of the IMDELLTRA® infusion for 22 to 24 hours following Cycle 1 Day 1 and Cycle 1 Day 8 in an appropriate healthcare setting. Recommend that patients remain within 1 hour of an appropriate healthcare setting for a total of 48 hours from the start of the infusion with IMDELLTRA® following Cycle 1 Day 1 and Cycle 1 Day 8 doses, accompanied by a caregiver. Inform both the patient and the caregiver on the signs and symptoms of CRS and ICANS prior to discharge. Ensure patients are well hydrated prior to administration of IMDELLTRA®. Please see IMDELLTRA® full Prescribing Information, including BOXED WARNINGS.

About Amgen 
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.

Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

Further, any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.

CONTACT: Amgen, Thousand Oaks
Brianna Wilkins, 513-284-9807 (media)
Casey Capparelli, 805-447-1746 (investors)

REFERENCES

International Agency for Research on Cancer. Trachea, bronchus and lung fact sheet. Global Cancer Observatory: Cancer Today. Published 2024. Accessed September 2, 2026. https://gco.iarc.who.int/today/en/fact-sheets-cancers/15/trachea-bronchus-and-lung. Oronsky B, Abrouk N, Caroen S, et al. A 2022 update on extensive stage small-cell lung cancer (SCLC). J Cancer. 2022;13(9):2945-2953. doi:10.7150/jca.75622. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-561. doi:10.1038/nrclinonc.2017.71. Cramer-van der Welle CM, Schramel FMNH, van Leeuwen AS, Groen HJM, van de Garde EMW; Santeon SCLC Study Group. Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer. Eur J Cancer Care (Engl). 2020;29(5):e13250. doi:10.1111/ecc.13250. Shaw J, Pundole X, Balasubramanian A, et al. Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer. Oncologist. 2024;29(12):1079-1089. doi:10.1093/oncolo/oyae234. Paz-Ares L, Borghaei H, Liu SV, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025;405(10495):2129-2143. doi:10.1016/S0140-6736(25)01011-6. Reck M, Mok TSK, Mansfield A, et al. Brief report: exploratory analysis of maintenance therapy in patients with extensive-stage SCLC treated first line with atezolizumab plus carboplatin and etoposide. J Thorac Oncol. 2022;17(9):1122-1129. doi:10.1016/j.jtho.2022.05.016. ClinicalTrials.gov. DeLLphi-305 clinical trial listing. Accessed July 16, 2026. https://clinicaltrials.gov/study/NCT06211036.  ClinicalTrials.gov. Tarlatamab clinical trial listings. US National Library of Medicine. Accessed July 2026. https://www.clinicaltrials.gov. Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537. doi:10.1158/1078-0432.CCR-20-2845. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11(1):22-30. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063-2075. doi:10.1056/NEJMoa2307980/ Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243. doi:10.1016/j.lungcan.2020.07.026. SOURCE Amgen

Zillow expects continued softness in the for-sale market, with newly pending sales and inventory growth both decelerating as affordability challenges push demand toward rentals

Home sales fell 0.6% year over year in August, a deceleration from July's 6% annual gain, according to Zillow's August Market Report. Newly pending listings, a leading indicator of future closings, fell 2.6% year over year in August, extending a rapid deceleration from June's 7.5% annual gain — even as the number of homes for sale continues to climb. The rental market shows signs of absorbing sidelined demand, with rents rising 2.5% year over year, nearly double the rate of home value growth. , /PRNewswire/ -- Home sales slipped 0.6% year over year in August and fell sharply from July, according to the Zillow® August Market Report. Mortgage rates holding above 6.5% — their highest level in a year — kept many buyers on the sidelines. Newly pending listings, a forward-looking measure of demand, fell 2.6% from a year ago, a sign that the slowdown could continue through the remainder of the year.

August's closed sales largely reflect contracts signed in July, when elevated rates were already discouraging many would-be buyers. The typical U.S. home value rose 1.3% from a year ago to $369,678, according to the Zillow Home Value Index, and the monthly mortgage payment on the typical home was 2% higher than last year. Rents are climbing, too, up 2.5% year over year to $1,948 nationwide, giving prospective buyers little relief on either side of the rent-versus-own equation. That annual rent growth figure is also reaccelerating, up from 2.3% last month and 2% a year ago, suggesting the rental market is absorbing some of the demand that has shifted away from the for-sale market.

Inventory continues to offer a modest bright spot, with 1.41 million homes for sale nationwide, up 3% from a year ago. But new listings fell 7.9% from July, and the share of listings with a price cut edged up to 26.3% — half a percentage point above last year — a sign that sellers are still having to adjust expectations to meet the market.

"The for-sale housing market took a step back in August, and mortgage rates above 6.5% are the primary culprit," said Mischa Fisher, chief economist at Zillow. "The combination of weak sales and even weaker pending sales points to a soft close to 2026. There are more homes for sale than a year ago, which is good news for buyers who are ready to move, but until rates ease, many households will likely stay on the sidelines a little longer as renting is still the more affordable substitute."

Home Values & Mortgage Payments

The typical U.S. home value is $369,678. The Zillow Home Value Index (ZHVI) fell 0.1% month over month in August. Home values are 1.3% higher than a year earlier. The monthly mortgage payment on a typical U.S. home is $1,897, assuming a 20% down payment and including estimates for taxes, insurance and maintenance. That is 2% higher than last year. Inventory

There were 1.41 million homes for sale nationwide in August. Active inventory was 3% higher than a year earlier. Inventory rose 0.2% from July. New for-sale listings totaled 356,934 in August, up 2.4% from a year earlier and down 7.9% from July. Sales

339,927 homes were sold in August, according to Zillow's sales count nowcast. That is 0.6% lower than a year earlier, and down 10.7% from July. Competition

Homes took a median of 27 days to go pending in August. That's the same as last year and two days longer than July. The share of listings with a price cut in August was 26.3%. That was up 0.5 percentage points from a year earlier and down 0.8 percentage points from July. 29.6% of homes sold above list price in July, the most recent data available. That was 0.8 percentage points higher than a year earlier and 1.1 percentage points lower than June. Rents

The typical rent nationwide is $1,948, according to the Zillow Observed Rent Index. That's 2.5% higher than a year earlier and up 0.2% from July. 39.2% of rental listings on Zillow offered a concession in August. That's 2.5 percentage points higher than a year earlier and down 0.6 percentage points from July. Local data can be found on Zillow's market explorer. The Zillow September Market Report is expected to be released October 6.

Zillow August Market Report

Metro Area*

Typical
Home
Value
(ZHVI)

Home
Value
Change:
MoM

Home
Value
Change:
YoY

Inventory
Change:
YoY

Sales
Count
Nowcast 
Change:
YoY

Typical
Rent
(ZORI)

Rent
Change:
MoM

Rent
Change:
YoY

United States

$369,678

-0.1 %

1.3 %

0.2 %

-0.6 %

$1,948

0.2 %

2.5 %

New York, NY

$739,324

0.4 %

5.2 %

-3.5 %

-2.3 %

$3,615

0.2 %

4.2 %

Los Angeles, CA

$957,612

-0.3 %

1.4 %

0.5 %

-2.0 %

$2,941

0.2 %

1.6 %

Chicago, IL

$359,782

0.3 %

5.1 %

-0.4 %

4.9 %

$2,210

-0.1 %

4.9 %

Dallas, TX

$361,463

-0.3 %

-1.9 %

-1.3 %

-2.1 %

$1,659

0.1 %

0.4 %

Houston, TX

$305,386

-0.3 %

-1.8 %

-1.1 %

-4.0 %

$1,643

0.0 %

0.0 %

Washington, DC

$575,362

-0.5 %

0.3 %

-2.6 %

-3.5 %

$2,433

0.2 %

0.8 %

Philadelphia, PA

$390,935

-0.1 %

2.5 %

-0.2 %

-2.7 %

$1,911

0.4 %

3.6 %

Miami, FL

$477,919

0.2 %

0.5 %

-2.6 %

-1.0 %

$2,666

0.2 %

1.6 %

Atlanta, GA

$377,813

-0.4 %

-1.5 %

0.6 %

-0.8 %

$1,853

0.3 %

2.0 %

Boston, MA

$737,482

-0.2 %

2.3 %

-4.2 %

0.1 %

$3,074

-0.7 %

2.4 %

Phoenix, AZ

$442,171

-0.4 %

-1.0 %

-0.9 %

-1.4 %

$1,722

0.1 %

0.7 %

San Francisco, CA

$1,134,525

-0.3 %

3.3 %

-1.1 %

2.5 %

$3,409

1.7 %

10.8 %

Riverside, CA

$583,081

-0.1 %

0.4 %

-0.9 %

-0.7 %

$2,541

0.3 %

2.8 %

Detroit, MI

$267,999

-0.1 %

1.8 %

5.0 %

-1.6 %

$1,524

0.4 %

3.8 %

Seattle, WA

$730,623

-0.8 %

-1.6 %

0.0 %

-6.5 %

$2,278

0.2 %

1.7 %

Minneapolis, MN

$390,396

-0.2 %

1.7 %

1.4 %

4.4 %

$1,719

0.1 %

3.5 %

San Diego, CA

$934,936

-0.4 %

1.0 %

-2.0 %

-6.3 %

$2,994

0.3 %

2.0 %

Tampa, FL

$359,285

-0.1 %

-0.6 %

-1.4 %

2.7 %

$2,001

0.1 %

-0.1 %

Denver, CO

$562,732

-0.5 %

-1.5 %

0.0 %

-1.6 %

$1,922

-0.1 %

-0.6 %

Baltimore, MD

$400,583

-0.4 %

0.4 %

0.2 %

3.7 %

$1,948

0.3 %

2.6 %

St. Louis, MO

$277,084

-0.1 %

3.3 %

-0.5 %

-5.3 %

$1,443

0.2 %

3.9 %

Orlando, FL

$383,656

-0.2 %

-1.4 %

-1.0 %

5.8 %

$1,942

0.0 %

0.7 %

Charlotte, NC

$384,369

-0.4 %

-0.7 %

-1.5 %

-2.4 %

$1,749

0.2 %

1.0 %

San Antonio, TX

$276,834

-0.3 %

-1.8 %

-0.5 %

5.7 %

$1,422

0.2 %

-1.3 %

Portland, OR

$545,374

-0.3 %

0.1 %

-0.4 %

1.4 %

$1,818

0.3 %

0.6 %

Sacramento, CA

$576,967

-0.3 %

0.2 %

-1.3 %

3.5 %

$2,282

0.3 %

1.7 %

Pittsburgh, PA

$232,967

0.1 %

0.3 %

-0.3 %

-6.5 %

$1,469

0.0 %

3.4 %

Cincinnati, OH

$309,495

-0.2 %

2.3 %

-1.8 %

3.7 %

$1,522

0.2 %

2.6 %

Austin, TX

$419,900

-0.5 %

-4.2 %

-3.2 %

2.0 %

$1,622

0.1 %

0.0 %

Las Vegas, NV

$423,354

-0.5 %

-2.8 %

1.8 %

2.1 %

$1,742

-0.3 %

0.1 %

Kansas City, MO

$329,538

0.0 %

3.8 %

-0.5 %

1.7 %

$1,529

0.3 %

3.6 %

Columbus, OH

$331,866

-0.1 %

1.3 %

-0.5 %

6.3 %

$1,521

0.5 %

2.6 %

Indianapolis, IN

$294,343

-0.1 %

1.0 %

2.9 %

-2.7 %

$1,552

0.3 %

3.3 %

Cleveland, OH

$255,245

0.3 %

4.0 %

1.6 %

1.4 %

$1,454

0.3 %

4.5 %

San Jose, CA

$1,544,638

-1.0 %

0.3 %

0.2 %

-5.7 %

$3,815

1.0 %

7.6 %

Nashville, TN

$453,322

-0.2 %

-0.3 %

0.7 %

1.0 %

$1,813

0.2 %

0.8 %

Virginia Beach, VA

$374,765

0.0 %

2.9 %

0.6 %

3.4 %

$1,891

1.0 %

6.6 %

Providence, RI

$528,018

0.1 %

3.7 %

2.3 %

-1.5 %

$2,167

0.1 %

4.3 %

Jacksonville, FL

$351,487

-0.1 %

0.0 %

-2.2 %

-1.0 %

$1,696

0.2 %

1.8 %

Milwaukee, WI

$391,398

0.1 %

5.5 %

-1.4 %

-2.9 %

$1,563

0.3 %

5.0 %

Oklahoma City, OK

$246,105

0.0 %

1.1 %

2.4 %

-4.9 %

$1,388

0.2 %

2.3 %

Raleigh, NC

$431,407

-0.4 %

-1.6 %

-1.4 %

4.7 %

$1,675

0.3 %

0.8 %

Memphis, TN

$244,845

-0.2 %

0.1 %

-0.5 %

0.8 %

$1,400

-0.1 %

1.0 %

Richmond, VA

$396,305

-0.1 %

2.7 %

3.5 %

-3.6 %

$1,729

-0.2 %

2.5 %

Louisville, KY

$280,808

-0.3 %

1.6 %

1.7 %

-0.2 %

$1,348

0.0 %

1.6 %

New Orleans, LA

$261,012

-0.3 %

1.6 %

-0.8 %

-2.7 %

$1,598

0.0 %

1.4 %

Salt Lake City, UT

$562,551

-0.2 %

1.0 %

6.2 %

0.1 %

$1,641

0.1 %

0.5 %

Hartford, CT

$404,670

0.2 %

5.2 %

1.0 %

1.2 %

$2,034

0.3 %

3.2 %

Buffalo, NY

$292,435

0.3 %

3.7 %

5.2 %

-3.8 %

$1,449

0.5 %

3.5 %

Birmingham, AL

$263,461

0.0 %

2.5 %

0.4 %

1.0 %

$1,433

0.8 %

2.0 %

*Table ordered by market size 

Forward-looking statements
This press release includes forward-looking statements about future housing market conditions, mortgage rates, rental trends and other economic factors. These statements are based on current expectations and assumptions, which are subject to change. Actual outcomes may differ materially due to changes in economic and market conditions. Forward-looking statements speak only as of the date of this release, and Zillow Group undertakes no obligation to update them.

About Zillow Group
Zillow Group, Inc. (Nasdaq: Z and ZG) is reimagining real estate to make home a reality for more and more people.

As the most visited real estate app and website in the United States, Zillow connects hundreds of millions of consumers with innovative technology, trusted agents and loan officers, and seamless digital solutions. With industry-leading tools and resources, Zillow supercharges real estate professionals so they can grow their businesses and deliver exceptional client experiences. For renters and housing providers, Zillow offers not only a robust marketplace but a set of end-to-end products and services to streamline applications, leases, payments and more.

Zillow's ecosystem spans the entire home journey — from dreaming and shopping to renting, buying, selling and financing.

Zillow Group's affiliates, subsidiaries and brands include Zillow®, Zillow Premier Agent®, Zillow Home Loans®, Zillow Rentals®, Zillow® New Construction, Trulia®, StreetEasy®, Out East®, HotPads®, Follow Up Boss®, ShowingTime®, dotloop® and Zillow® Closing.

All marks herein are owned by MFTB Holdco, Inc., a Zillow affiliate. Zillow Home Loans, LLC is an Equal Housing Lender, NMLS #10287 (www.nmlsconsumeraccess.org). © 2026 MFTB Holdco, Inc., a Zillow affiliate.

(ZFIN)

SOURCE Zillow, Inc.

The oil market is unlikely to return to normal levels anytime soon.

*Stock prices used were the afternoon prices of Sept. 5, 2026. The video was published on Sept. 7, 2026.

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Occidental Petroleum. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) of the September 14, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

Should You Join The Regeneron Class Action Lawsuit:

Do you, or did you, own shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)?Did you purchase your shares between August 1, 2025 and May 15, 2026, inclusive?Did you lose money in your investment in Regeneron Pharmaceuticals, Inc.? What To Do Next:

Investors are encouraged to act promptly and submit a form at Regeneron Pharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

If you wish to serve as lead plaintiff for the Class, you must file papers by September 14, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About The Lawsuit:

A lawsuit was filed on behalf of investors (the “Class”) who purchased or acquired the common stock of Regeneron between August 1, 2025 and May 15, 2026, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.

The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, Regeneron common stock traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.

About Bernstein Liebhard:

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - September 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Regeneron's Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.

On April 29, 2026, Defendants disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, Regeneron's stock price fell $45.41, or approximately 6.2%, to close at $686.36 per share on April 29, 2026.

On May 15, 2026, Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57, or approximately 9.8%, to close at $629.68 per share on May 18, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Regeneron's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Regeneron class action, go to www.faruqilaw.com/REGN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Regeneron Securities Class Action Lawsuit:

What is the Regeneron securities fraud lawsuit about?

Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased Regeneron securities during the Class Period. The lawsuit alleges that Regeneron and certain of its officers made materially false and misleading statements regarding the Phase III Fianlimab-Libtayo clinical study. Specifically, the complaint alleges that defendants concealed that the study's preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was allegedly failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint. The alleged fraud is said to have come to light through two disclosures: first, on April 29, 2026, when defendants announced an expansion of patients eligible for analysis of progression-free survival — causing Regeneron's stock to fall approximately 6.2% — and then on May 15, 2026, when Regeneron announced that the Phase III trial did not reach statistical significance for its primary endpoint, causing the stock to fall an additional approximately 9.8%.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities on the NASDAQ between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased Regeneron securities during the Class Period and suffered a loss may potentially share in any recovery obtained on behalf of the class. Investors are encouraged to review their trading records to determine whether their purchases fall within the Class Period. Participation in the litigation does not require investors to take any active litigation role beyond filing a timely claim if a recovery is ultimately achieved.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including working with counsel to make key strategic decisions regarding the case. Any investor who purchased Regeneron securities during the Class Period and suffered losses may move the court for appointment as lead plaintiff, but must do so no later than September 14, 2026, which is the court-established deadline for such motions. Courts generally appoint the movant with the largest financial interest in the relief sought who also satisfies the adequacy requirements of the applicable securities laws. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in or potentially share in any recovery that may result from this litigation. Those who do not seek lead plaintiff status may still submit a claim and may be eligible to receive a portion of any settlement or judgment obtained on behalf of the class.

What should investors do if they purchased Regeneron stock during the Class Period?

Investors who purchased Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026 are encouraged to promptly review their brokerage and trading records to confirm the timing and size of their purchases and any resulting losses. Investors should take steps to preserve all relevant documentation, including trade confirmations, account statements, and any communications relating to their Regeneron holdings, as such records may be material to any future claim. Given that the lead plaintiff motion deadline is September 14, 2026, investors who wish to be considered for that role should act in advance of that date. Investors may wish to consult with Faruqi & Faruqi, LLP to better understand their legal rights and options before the deadline passes. Retaining counsel or seeking lead plaintiff status is not required to participate in any potential class recovery, but timely action is advisable to preserve all available options.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Regeneron securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313369

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

SAN FRANCISCO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.

The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys.

View our latest video summary of the allegations: youtu.be/rsW1-f8ARRs

Class Period: Aug. 1, 2025 – May 15, 2026
Lead Plaintiff Deadline: Sept. 14, 2026
Visit: www.hbsslaw.com/regn
Contact the Firm Now: [email protected]
                                       844-916-0895

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:

The litigation is focused on the propriety of Regeneron’s repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the “Study”).

The Study’s primary endpoint was progression-free survival (“PFS”) and Regeneron has characterized the combination as a “potential blockbuster.” “Events” – disease progression or death – determined the timing and statistical power of the primary PFS analysis.

The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study’s preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely.

Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial’s achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are “because the test arms are performing well.”

The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that “t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months.”

One prominent analyst reportedly questioned whether the decision was made because, in contrast to management’s expressed confidence, the “underlying PFS benefit may be insufficient to show statistical significance.”

Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to “slow event rates,” occurred nearly six months ago, and was “submitted it to all the global regulatory authorities in November, December timeframe.”

Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the “trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS).”

“We’re focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn’t really there,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims in the suit.

If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Regeneron case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4d42c461-d988-4a68-b62e-94e8ce45b906

Regeneron (REGN) Securities Class Action Filed - Sept 14, 2026 Lead Plaintiff Deadline - Act Now Regeneron (REGN) Securities Class Action Filed - Sept 14, 2026 Lead Plaintiff Deadline - Act Now

ASML Stock Rallies as Samsung, TSMC and Intel Advance High-NA Plans Summary

A planned shift to 12-inch photomasks could raise High-NA equipment throughput by as much as 40%

ASML Holding ASML gained about 2% on Tuesday as investors assessed progress by major chipmakers toward adopting the company's newest High-NA extreme ultraviolet lithography systems.

Samsung Electronics, Taiwan Semiconductor Manufacturing and Intel are moving forward with plans to use the advanced equipment. The companies are also working with ASML on a shift from six-inch photomasks to a 12-inch format.

ASML Holding (ASML) said the larger masks could raise High-NA system throughput by as much as 40%. Higher throughput could help chip manufacturers improve production efficiency as demand for processors used in artificial intelligence applications continues to expand.

The companies are also taking a longer-term approach to the technology. Taiwan Semiconductor Manufacturing (TSM) and ASML plan to establish a 12-inch mask test line by 2031, with commercial manufacturing targeted for 2033.

ASML Chief Technology Officer Marco Pieters said the larger mask format could support higher productivity from High-NA equipment. Intel (INTC) and Samsung Electronics are also participating in the development effort, highlighting broader industry interest in the next generation of lithography technology.

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

One of the best investors riding the artificial intelligence (AI) revolution is Stanley Druckenmiller at the Duquesne Family Office. Druckenmiller is a famous trend follower and was one of the early traders to buy into Nvidia (NVDA -2.01%) as a way to ride the AI boom.

Today, Duquesne and Druckenmiller own two megacap stocks benefiting from AI infrastructure spending, but his top holding by far is an undiscovered winner in genetic testing that few investors are talking about.

Stanley Druckenmiller. Image source: Getty Images.

Investing in AI infrastructure Regarding AI infrastructure, Druckenmiller holds stakes in two megacap technology companies in the United States: Amazon (AMZN -0.60%) and Alphabet (GOOGL -0.03%) (GOOG +0.02%). Today, we can see these bets primarily benefiting from growing AI spending.

Amazon's cloud computing division -- Amazon Web Services (AWS) -- is the leader in its sector and saw revenue grow 37% year-over-year last quarter to $42.2 billion. There is a massive backlog of spending on its AI cloud services, which power fast-growing start-ups like Anthropic and OpenAI. CEO Andy Jassy recently mentioned that AWS could grow to $1 trillion in annual revenue, driven by cloud market share gains and rising total spending on computing infrastructure worldwide.

Alphabet is a bit of a different bet, as it combines the fast cloud growth with the dynamics of the consumer and enterprise AI application economy. The Google Cloud division grew revenue by 82% year-over-year to $24.8 billion, catching up quickly to AWS, though it remains much smaller. Alphabet is growing quickly with its Gemini chatbot, now serving nearly 950 million monthly users, but its Google Search division faces significant competitive pressures.

Overall, these two stocks are a small % of the Duquesne portfolio today, but they have been nice long-term winners for Druckenmiller.

An underfollowed top holding in genomics Notably, close to 20% of Druckenmiller's portfolio, as of his latest quarterly filing -- excluding international holdings -- is a stock called Natera (NTRA -1.23%). Natera is a disruptor in the diagnostics segment and uses its technologies for analyzing tumors and women's health during pregnancies, along with organ transplants.

Premium Feature

Moneyball Superscore

87/100

Today's Change

(

-1.23

%) $

-4.04

Current Price

$

324.14

Last quarter, Natera's revenue grew 38% year over year to $753 million, due to an increase in tests performed. Full-year revenue guidance was raised as well. Accelerating business momentum is why the stock has been a huge winner for Druckenmiller.

Duquesne first invested in Natera in Q3 of 2022, when the share price was between $35 and $50. Today, it trades at $328, closing in on about 10 times the initial cost basis (the exact figure is unknown). Natera has been a massive winner for Druckenmiller, which is why it is the largest U.S. stock he owned at the end of last quarter.

Why doesn't he own Nvidia anymore? Curiously, even though he was an early bettor on Nvidia, Druckenmiller's Duquesne Family Office currently does not own any of the AI chipmaker. He said in 2024 that he sold Nvidia after it went on a massive run, with sales coming at a split-adjusted price of $80 to $90. Today, Nvidia trades at $230.

The reason for the sale was valuation concerns, but he subsequently said it was a mistake not to let his winners run. Nvidia has not been in the Duquesne portfolio since early 2024.

Druckenmiller's current bet on AI semiconductors is Taiwan Semiconductor Manufacturing. This is the company that actually builds Nvidia chips (Nvidia just designs them). It could be another way to take advantage of the AI trend, but with a stock trading at a more reasonable valuation and a monopoly position in advanced chipmaking at the moment.

Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases Strong clinical evidence demonstrates the device's high rates of safety and effectiveness in treating AFib patients FDA approval of TactiFlex Duo strengthens Abbott's expanding PFA portfolio following recent cardiac ablation approvals in the U.S., Europe, Asia and Latin America , /PRNewswire/ -- Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation (AFib). The U.S. approval of this dual-energy catheter, the latest generation of Abbott's cardiac ablation technology, marks a significant milestone in Abbott's commitment to advancing therapies that help physicians treat complex heart rhythms with greater precision and flexibility. Abbott will soon begin cases with broader commercial adoption across the country in the coming weeks.

Why cardiac ablation matters for people with AFib
For the 10.5 million people in the U.S. who live with a heart that beats too fast, too slow or in an irregular way, treatment is critical as AFib increases the risk of serious complications, including stroke.1,2 While many people are treated with medications, others require cardiac ablation, a minimally invasive procedure that targets the tissue responsible for abnormal electrical signals in the heart.

TactiFlex Duo is Abbott's latest ablation catheter designed to give physicians more flexibility when treating AFib. The technology allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy, or a combination of both during a procedure, helping them tailor treatment to each patient's needs. Abbott's EnSite™ X EP System also provides physicians with real-time feedback as an integrated mapping solution with the PFA Index (PI), a tool designed to assess lesion formation during ablation with TactiFlex Duo. The dual-energy approach means physicians can create precise therapeutic lesions, or small areas of scar tissue, that block the abnormal electrical signals causing an irregular heartbeat while helping minimize the impact on surrounding healthy tissue. Successfully treating these areas can help restore the heart's normal rhythm and improve outcomes for patients living with AFib. 

"Electrophysiology is rapidly evolving as physicians adopt new technologies that improve the safety and effectiveness of AFib treatment," said Atul Verma, M.D., Director of Cardiology at the McGill University Health Centre in Montreal, Canada, and a globally recognized expert in pulsed field ablation technology. "TactiFlex Duo provides physicians with greater flexibility during procedures, and when it is combined with the high-resolution 3D visualization available through Abbott's EnSite X mapping system, physicians have a suite of practice-changing tools to confidently treat patients with complex AFib."

Safety and effectiveness data support TactiFlex Duo FDA approval  
The FDA approval of TactiFlex Duo was secured based on the results from Abbott's FlexPulse IDE study. Late-breaking data from the study recently presented at the European Society of Cardiology (ESC) Congress 2026, which was simultaneously published in EP Europace, showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib (irregular heart rhythm episodes that come and go).

"TactiFlex Duo represents an important advancement as Abbott builds the industry's most comprehensive electrophysiology portfolio," said Uri Yaron, senior vice president of Abbott's electrophysiology business. "From diagnosis, mapping and intracardiac ultrasound imaging to advanced treatments for the most complex arrhythmias, Abbott is uniquely positioned to support physicians at every stage of patient care. By continuing to expand our PFA portfolio and integrate innovative technologies across cardiovascular care, we're helping physicians navigate increasingly complex procedures while ensuring more patients receive the right care at the right time."

Regulatory momentum across Abbott's PFA portfolio
The U.S. FDA approval of TactiFlex Duo further expands Abbott's portfolio of technologies designed to help physicians treat patients with cardiac arrhythmias. It is the company's fifth major electrophysiology approval in just over a year, following Europe's Amulet 360™ and TactiFlex Duo CE Mark approvals this year, and U.S. and European approvals of the Volt™ PFA System in 2025.

Frequently Asked Questions

What is TactiFlex Duo?
TactiFlex Duo is an advanced cardiac ablation catheter designed to treat irregular heart rhythms. Its dual-energy feature combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single device, allowing physicians to tailor treatment to each patient's unique needs during AFib ablation procedures.  

How do physicians know the precise locations in the heart to treat patients with TactiFlex Duo?  
TactiFlex Duo is integrated with Abbott's EnSite X EP System, a sophisticated mapping system that creates highly detailed three-dimensional maps of the heart to help doctors find and treat the source of an irregular heartbeat. Working together with Abbott's Advisor™ HD Grid X mapping catheter, ViewFlex™X ICE (intracardiac echocardiography) catheter and EnSite Echo Module, the integrated portfolio is designed to give physicians real-time images of the ablation catheter's positioning and movement, and a digital model of the patient's heart throughout a procedure. The EnSite X EP System also provides physicians with real-time information – called PFA index – which shows how the small areas of scar tissue created by TactiFlex Duo's pulsed field energy develop during an ablation procedure.3 

Who may need an ablation using TactiFlex Duo?
Patients with atrial fibrillation, particularly those with complex anatomy, prior or failed ablations or other challenging clinical situations, may benefit from treatment with TactiFlex Duo as determined by their physician. 

What are the patient benefits of being treated with TactiFlex Duo?
The catheter offers physicians greater procedural flexibility and precision through dual-energy capabilities, helping treat irregular heart rhythms while reducing the potential for damage to surrounding tissue. Clinical data has shown the technology to be safe and effective.

For U.S. important safety information go to:

TactiFlex Duo Ablation Catheter, Sensor Enabled

Volt™ PFA System

EnSite™ X EP System 

Advisor HD Grid X Mapping Catheter, Sensor Enabled™

ViewFlex X ICE Catheter, Sensor Enabled™ and EnSite Echo Module

The Amulet 360™ Left Atrial Appendage Occluder is approved for investigational use only in the U.S.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic 3 medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

________________________________

1 Noubiap JJ, Tang JJ, Teraoka JT, Dewland TA, Marcus GM. Minimum National Prevalence of Diagnosed Atrial Fibrillation Inferred From California Acute Care Facilities. J Am Coll Cardiol. 2024;84(16):1501-1508. doi:10.1016/j.jacc.2024.07.014.

2 About Atrial Fibrillation. Centers for Disease Control. (n.d.). About Atrial Fibrillation | Heart Disease | CDC.

3 Friedman, et al. (2025 September) Development of a PFA index to guide energy delivery with a force sensing flexible, irrigated tip catheter [Oral presentation]. ESC 2025, Madrid, Spain.

SOURCE Abbott

Key Takeaways NVO's STEP Young study showed greater BMI reduction with semaglutide versus placebo at week 68.40.4% of children on semaglutide were no longer classified as having obesity after week 68.Semaglutide's safety profile was consistent with prior pediatric and adult studies, with no new concerns. Novo Nordisk (NVO - Free Report) announced positive data from the phase III STEP Young study evaluating once-weekly subcutaneous semaglutide, in combination with a reduced-calorie diet and increased physical activity, in children with obesity aged six to under 12 years.

More on the STEP Young Study DataThe phase III STEP Young study met its primary endpoint by demonstrating a greater reduction in body mass index (BMI) at week 68 following treatment with semaglutide versus placebo. Both treatment groups received lifestyle modification, including a reduced-calorie diet and increased physical activity.

Importantly, 40.4% of children who were treated with once-weekly subcutaneous semaglutide were no longer classified as having obesity after week 68, compared with none in the placebo group. More than 85% of children had class II or III severe obesity at baseline.

Per the company, two out of five children treated with semaglutide reduced their BMI below the obesity threshold, reaching either a normal-weight or overweight classification, compared with none of the children receiving placebo.

The overall safety and tolerability profile of semaglutide seen in the STEP Young study was consistent with prior pediatric and adult studies, with no new safety concerns reported.

The company plans to present detailed data from the phase III STEP Young study at the Obesity Society’s annual meeting in November.

NVO’s Price PerformanceYear to date, shares of Novo Nordisk have declined 5.3% against the industry’s rise of 16.4%.

Image Source: Zacks Investment Research

NVO Thrives on Semaglutide-Based MedicinesNovo Nordisk markets its semaglutide-based medicines under the brand names Ozempic (injection and oral pill) and Rybelsus (oral tablet) for type II diabetes (T2D), and Wegovy (injection and oral pill) for chronic weight management.

The company’s semaglutide-based medicines continue to demonstrate benefits beyond blood sugar control and weight loss, including reducing cardiovascular (CV) risk and improving kidney disease outcomes.

Novo Nordisk has been witnessing strong success with its GLP-1 medicines, Wegovy for obesity and Ozempic and Rybelsus for T2D.

In the first half of 2026, total reported Obesity care sales increased 20% year over year in DKK, or 24% at constant exchange rates, driven by higher sales across the Wegovy portfolio, including incremental sales from the newly launched Wegovy pill.

In late December, the FDA approved NVO’s 25 mg oral semaglutide (Wegovy pill) for obesity and CV disease, which was subsequently launched in early January. The Wegovy pill is also approved in the EU.

NVO Faces Rising Competitive PressureNovo Nordisk faces intense competition from Eli Lilly (LLY - Free Report) in the obesity market. Lilly's Mounjaro for T2D and Zepbound for obesity have earlier demonstrated superior weight-loss efficacy in clinical studies, allowing the company to gain market share steadily. Despite being on the market for a shorter duration, these drugs have become LLY’s key top-line drivers.

Lilly has also secured FDA approval for its oral GLP-1 drug, orforglipron, for adults with obesity or overweight with weight-related medical problems, marketed under the brand name Foundayo.

While Novo Nordisk and Eli Lilly currently dominate this space, smaller biotechs like Structure Therapeutics (GPCR - Free Report) and Viking Therapeutics (VKTX - Free Report) are also advancing GLP-1–based therapies for treating obesity.

Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist (RA), VK2735, is being developed in both oral and subcutaneous formulations for the treatment of obesity. VKTX plans to advance oral VK2735 into phase III development for obesity in the fourth quarter of 2026.

Structure Therapeutics’ phase II ACCESS program on its orally administered small molecule GLP-1 RA, aleniglipron, demonstrated significant weight loss across all doses. Based on such encouraging results, GPCR has initiated dosing patients in its late-stage ACCOMPLISH program to evaluate aleniglipron for chronic weight management.

NVO Zacks RankNovo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.

A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading. The selloff is unfolding even as Amgen posted a positive Phase 3 readout of its own in small cell lung cancer, an unusual split that captures how brutally the market can price competitor risk in biotech.

Amgen stock is down 10% to $394.38 at midday, interrupting a gain of 23% year to date (YTD) heading into the session. The move carries added weight because Amgen holds the fourth-largest position in the Dow Jones Industrial Average, so today’s decline pressures that index alongside health care specifically.

Meanwhile, Eli Lilly (NYSE:LLY) shares are down 2% to $1,124.77 on read-through concerns about its own Lp(a) program. As for Novartis stock, it’s tumbling 14% to $137.63 on Tuesday afternoon. The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is down 0.37%, so today’s pharma-sector pain isn’t washing across the broad tape. That gap between the biotech names and the benchmark tells you the market is pricing pipeline risk at the sector level.

Pelacarsen Miss Rattles the Lp(a) Class Novartis said last Thursday that pelacarsen, an experimental heart drug developed with Ionis Pharmaceuticals, failed to reduce cardiovascular risk in a late-stage trial. The Novartis 8,323-patient Phase III study lowered Lp(a) levels while missing its primary composite endpoint covering cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularization.

Citi analysts said the Lp(a) hypothesis has been weakened, with additional data needed to establish whether the shortfall came from the drug’s mechanism, the trial’s design, or the underlying idea that lowering Lp(a) reduces cardiovascular risk. Amgen and Eli Lilly are both developing Lp(a)-lowering therapies using different technical approaches, so a class-defining failure at a rival forces investors to reweight the odds on every remaining program.

Amgen’s Own Trial Delivered a Win Here’s the wrinkle the market is missing. Amgen also announced this morning that its Phase 3 DeLLphi-305 study met its primary endpoint, showing a statistically significant improvement in overall survival for IMDELLTRA. AstraZeneca (NASDAQ:AZN) partly funded the study and supplied Imfinzi, the comparator in the trial.

Amgen’s IMDELLTRA-plus-Imfinzi regimen is being studied as a first-line maintenance treatment in extensive stage small cell lung cancer, one of the toughest settings in oncology. The readout arrived with hard survival data, an endpoint that carries commercial weight immediately, while a mechanistic Lp(a) result needs another round of confirmation.

Amgen’s cholesterol franchise still matters here. Repatha, its PCSK9 inhibitor, generated Q1 2026 revenue of $876 million on 34% year over year (YoY) growth and 35% volume growth, making it one of Amgen’s fastest-growing brands. Its longer-dated Lp(a) bet, Olpasiran, sits in the Phase 3 OCEAN(a)-Outcomes cardiovascular outcomes trial, and it’s now the pipeline asset most exposed to today’s class re-rating, according to Amgen.

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) carries Amgen and Eli Lilly as major holdings. A same-day selloff in both names weighs on the fund, even though Novartis isn’t a listed component of the ETF.

Scorecard on the Session Ticker Session Move YTD AMGN -10% +21% LLY -2% +5% NVS -14% -0.76% The gap between the size of Amgen stock’s decline and the modest moves elsewhere shows the market is treating today as a program-level revaluation for the Lp(a) class. Amgen’s YTD anchor is included because the interrupted rally frames the setback in the context of what had been a strong year.

What to Watch Next Amgen stock is being punished for a competitor’s failed trial on the same morning its own trial succeeded, and holding both facts at once is the whole exercise. A pipeline is priced on expected approvals, and the pelacarsen miss lowers the odds on the Olpasiran program Amgen has invested years in. The DeLLphi-305 readout, however, sits closer to commercialization and delivered concrete survival data.

Eli Lilly stock’s shallower decline is a reminder that these are different molecules at different stages, and a class-wide selloff prices them as if they were the same bet. Lilly’s VERVE-102 base editor showed a single dose reduced PCSK9 by up to 88% and LDL-C by up to 62% with durable effects, a mechanism distinct from pelacarsen’s antisense approach. Whether that mechanistic distance ultimately shields Lilly’s cardiovascular program depends on how the Lp(a) hypothesis holds up in the next set of trial readouts across the industry.

Investors sizing their exposure to large-cap pharma may want to keep their positions moderate until follow-up commentary lands from cardiology leaders, since the distinction between a failed drug and a failed idea can’t be settled from a single topline result. Moreover, traders can watch for Amgen’s presentation at the 2026 Wells Fargo Healthcare Conference as the next scheduled catalyst that could reframe the Lp(a) narrative.

Contact [email protected] for any questions or corrections.

IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.

Continuum Advisory LLC lowered its position in Danaher Corporation (NYSE:DHR – Free Report) by 87.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 481 shares of the conglomerate’s stock after selling 3,498 shares during the period. Continuum Advisory LLC’s holdings in Danaher were worth $92,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Main Street Group LTD purchased a new stake in shares of Danaher in the 1st quarter worth about $25,000. N.E.W. Advisory Services LLC purchased a new position in Danaher during the 2nd quarter valued at about $25,000. JPL Wealth Management LLC purchased a new position in Danaher during the 3rd quarter valued at about $25,000. WFA of San Diego LLC acquired a new position in Danaher during the second quarter worth about $26,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Danaher in the fourth quarter valued at about $27,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 0.1% Shares of DHR opened at $207.46 on Tuesday. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a market capitalization of $145.84 billion, a PE ratio of 36.85, a price-to-earnings-growth ratio of 2.59 and a beta of 0.78. The stock has a fifty day moving average of $202.03 and a two-hundred day moving average of $192.15. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the previous year, the business earned $0.77 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, analysts forecast that Danaher Corporation will post 8.53 EPS for the current year. Analysts Set New Price Targets Several analysts have recently commented on DHR shares. DZ Bank began coverage on shares of Danaher in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target on the stock. HSBC reduced their target price on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Guggenheim lowered their target price on Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Piper Sandler assumed coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target for the company. Finally, Wells Fargo & Company reduced their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Get Our Latest Stock Report on Danaher

About Danaher (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Recommended Stories Five stocks we like better than Danaher 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Even though major U.S. stock market indexes sit near all-time highs, it's possible to find beaten-down companies worth investing in. Consider Medtronic (MDT -1.89%) and MercadoLibre (MELI -2.63%), both leaders in their respective fields. These corporations have faced some challenges, but they remain excellent buy-and-hold options, despite lagging the market lately. Let me explain.

Image source: Getty Images.

1. Medtronic After spending most of the first half of the year moving south, Medtronic has been rebounding over the past three months. The company's financial results have something to do with that. Take the medical device specialist's first-quarter 2027 update for the period ended July 31. Medtronic’s revenue jumped 13.7% year over year -- a strong showing for the company -- to $9.8 billion. The healthcare leader's adjusted earnings per share (EPS) were $1.45, up 15.1% year over year. Medtronic also raised its revenue growth and EPS guidance for its full fiscal year 2027.

It was a beat-and-raise quarter for the company, which explains why its shares jumped after its earnings release. Still, Medtronic stock is down 2% year to date as of writing, while the S&P 500 has gained 12%. At current levels, the stock might be a steal, especially for investors focused on the long game. Medtronic is riding the wave of several growth drivers, will benefit from others in the medium term, and is also working to improve margins.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

-1.89

%) $

-1.78

Current Price

$

92.39

Right now, the company's cardiac ablation (a procedure that treats irregular heartbeats) solutions are doing much of the heavy lifting, thanks to innovative products it has launched in this niche in recent years. In the company's first quarter, cardiac ablation solutions revenue jumped 88% year over year.

Further, over the next few years, Medtronic should see its Hugo robotic-assisted surgery system gain traction and begin meaningfully contributing to its financial results, especially given the large addressable market in this field. And the company's planned separation of its diabetes care segment should help boost margins, since this unit has lower operating margins. Medtronic looks well-positioned to continue posting solid financial results while maintaining its dividend program.

The company has raised its payouts for 49 consecutive years, an impressive achievement that puts it close to joining the ranks of Dividend Kings, or corporations with at least 50 consecutive annual payout increases. Medtronic is an excellent buy-and-hold option for long-term income seekers.

2. MercadoLibre MercadoLibre has faced increased competition in the e-commerce market in South America. The company has responded by making significant investments in the business that are currently harming profits and margins. For instance, MercadoLibre has expanded free shipping offerings (by lowering the threshold for eligible transactions) in some markets. The e-commerce specialist is also doubling down on its fintech ambitions.

MercadoLibre is expanding credit card offerings across various regions, an initiative that is reducing net income due to expected credit loss provisions. In the second quarter, MercadoLibre's revenue grew by almost 50% year over year to $10.2 billion. But the company's EPS dropped to $9.19, down from the $10.31 reported in the year-ago period.

Despite the challenges -- and the reduced bottom line -- MercadoLibre is a great stock to buy. Here are three reasons why. First, MercadoLibre's initiatives, including expanded free shipping, have worked wonders for other e-commerce specialists by boosting gross merchandise volume and revenue. MercadoLibre has also benefited from similar efforts in the past, and its most recent attempts are already positively impacting financial results.

Premium Feature

Moneyball Superscore

86/100

Today's Change

(

-2.63

%) $

-52.11

Current Price

$

1,926.25

Second, the e-commerce leader's efforts should expand its ecosystem and competitive moat. MercadoLibre benefits from network effects and high switching costs. A larger pool of customers and merchants, combined with broader fintech offerings, can strengthen the company's moat. Third, there is a vast runway for growth in the markets where MercadoLibre operates. The company points out, for instance, that a substantial percentage of people in some of the regions where it does business are underbanked.

MercadoLibre will also benefit from the continued growth of the e-commerce market. The stock is down 18% over the past year, but the company's future seems bright. Investors should consider initiating a position before the stock bounces back.

Medtronic’s Stars Are Aligning for a Price RecoveryMedtronic NYSE: MDT executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.

Speaking at the Wells Fargo Healthcare Conference, Chairman and Chief Executive Officer Geoff Martha said medical technology is benefiting from innovations that can improve outcomes while potentially lowering costs and expanding patient access. He described AI and robotics as “force multipliers” that enable the company to diagnose conditions earlier and personalize treatment at scale.

Get Medtronic alerts:

Medtronic Bottoms, Healthy Rebound AheadMartha said Medtronic’s AI applications are centered on structured physiological, device and procedure data rather than broad large-language-model applications. He pointed to GI Genius, the company’s AI-supported colonoscopy technology, as an example. In the U.S., he said the technology is becoming a standard of care after clinical trials found that 25% to 50% of polyps could be missed even at leading centers. He also cited its use in India, where less-experienced physicians were able to achieve diagnostic results comparable to those in the U.S.

Limited ACA Exposure, China Stabilization Addressing concerns around healthcare policy changes, Martha said Medtronic has limited exposure to Affordable Care Act-related programs. He said the company’s procedure mix is largely acute rather than elective, with approximately two-thirds of its payer mix tied to Medicare, 25% to commercial insurance and less than 10% to Medicaid. ACA-related programs account for less than 1% of Medtronic’s global revenue, he said.

3 Reasons Analysts Love DexComIn China, Chief Financial Officer Thierry Piéton said Medtronic’s revenue exposure has fallen to between 5% and 6% following volume-based procurement, or VBP, changes. However, he said the company believes the impact of VBP is now largely behind it and that China has returned to a more normal operating environment. Martha said Medtronic remains committed to the country, which he characterized as a profitable growth market as the government expands access to higher-end healthcare.

First-Quarter Growth and Franchise Performance Piéton said Medtronic reported first-quarter growth of 13.7% including an extra week in the period, or about 7% after adjusting for that extra week. He said the company’s large established franchises are growing faster than in prior periods, while several newer businesses could provide additional expansion.

Cardiac rhythm management: Revenue rose 15% including the extra week, or about 9% on an adjusted basis, driven by EV-ICD, conduction system pacing and leadless pacemaker technology, according to Piéton. Spine: Piéton said the Stealth AXiS platform has helped Medtronic offer navigation, visualization and robotic-assistance tools alongside implants, supporting customer retention and pricing. Surgical: The surgical business performed well, including acute care and monitoring, he said. High-growth opportunities: Piéton identified cardiac ablation, Symplicity renal denervation for hypertension, Altaviva for urinary incontinence and Hugo surgical robotics as four potentially multibillion-dollar opportunities. Martha said Medtronic has effectively doubled its investment in innovation in recent years when both internal research and development and external investments, including venture investments and acquisitions, are considered. He said the company’s growth is diversified by geography, business line and a mix of organic and inorganic investment.

Cardiac Ablation and Robotics Expansion Cardiac ablation was a notable driver, with Martha describing the business as exceeding the company’s earlier expectation of reaching $2 billion in sales. Piéton said the market is growing at a mid-teens rate, or around 15%, and Medtronic expects to grow at more than 2.5 times the market rate for the full fiscal year. He said the company grew its capital-equipment installed base by 40% in the fourth quarter and by 35% sequentially in the first quarter, which should support future catheter demand.

Medtronic’s Sphere-9 catheter is currently a major contributor to ablation growth, Piéton said. The company has launched Sphere-360 in Europe and is conducting U.S. clinical trials. Martha said the company recently completed enrollment in the Sphere-360 trial, which includes a 12-month follow-up before submission.

On surgical robotics, Martha discussed Medtronic’s $700 million investment and distribution agreement with Cornerstone, which provides rights to the Sentire surgical robot in 50 countries outside the U.S. He said the deal broadens Medtronic’s offering in international markets, where hospitals and health systems may seek alternatives tailored to local needs and pricing.

Martha said Hugo, Medtronic’s surgical robotics platform, is focused on developed markets. The company expects to surpass 50,000 cumulative procedures and reach approximately 250 cumulative installed systems globally by year-end. Piéton said Hugo is already contributing to surgical-business growth, though the company did not provide specific revenue figures. Martha said Hugo has reached 99% uptime in the U.S. following software updates and refinements during its controlled launch.

Pipeline, Portfolio and Investor Day Martha said Medtronic sees renal denervation as a future billion-dollar product opportunity. He said the company is working to expand payer coverage and referral pathways for its hypertension therapy after a national U.S. coverage decision. He also said Medtronic plans more direct-to-consumer marketing in selected cities beginning in the fall.

Medtronic continues to evaluate tuck-in acquisitions, Piéton said, noting that the company has announced approximately $2.7 billion to $2.8 billion in deals over the last 12 months, compared with roughly $400 million to $500 million annually in the preceding six or seven years. He said the company intends to balance acquisition-related dilution with overhead leverage and improved gross margins.

The company also reiterated its intention to separate its MiniMed diabetes business. Piéton said Medtronic’s guidance assumes MiniMed remains consolidated for the full fiscal year, and that the ultimate earnings-per-share impact of a separation would depend on timing. He said MiniMed’s business performance has improved, but the intent to separate the business has not changed.

Medtronic plans to provide additional details on its growth outlook, new drivers and long-term financial framework at an Investor Day in December in Charlotte, North Carolina. Martha said the event will include demonstrations of the company’s robotics and digital technology ecosystems as well as physician perspectives.

About Medtronic (NYSE:MDT)Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Medtronic Right Now?Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.